Table 4. Univariate analysis of sustained viral response (SVR) rates observed from the IDEAL pharmacogenomics cohort for IL28B heterozygous patients with high or low low-density lipoprotein cholesterol (LDL-C) (≤/>130 mg/dL) compared with other prognostic factors associated with SVR.
Clinical factor | LDL-C > 130 mg/dL SVR % (n/N) | LDL-C ≤ 130 mg/dL SVR % (n/N) | P-value* |
---|---|---|---|
HCV RNA ≤600 000 IU/mL | 71% (12/17) | 53% (59/112) | 0.00014 |
HCV RNA >600 000 IU/mL | 43% 37/87 | 24% (126/532) | |
F0–F2 METAVIR fibrosis | 47.9% (45/94) | 30.6% (175/571) | 0.00033 |
F3–F4 METAVIR fibrosis | 40.0% (4/10) | 13.7% (10/73) | |
Non-African American | 53.8% (42/78) | 30.6% (165/533) | 0.00008 |
African American | 26.9% (7/26) | 18.0% (10/73) | |
Normal fasting blood glucose | 50.0% (43/86) | 31.5% (165/524) | 0.00030 |
Abnormal fasting blood glucose | 33.3% (6/18) | 16.7% (20/120) |
Cochran–Mantel–Haenszel test compares SVR rates for high vs low LDL-C after adjusting for hepatitis C virus (HCV) RNA level, METAVIR fibrosis, race, abnormal fasting glucose.